Business Wire

CIVITAS-INVESTMENT

18.6.2020 08:02:13 CEST | Business Wire | Press release

Share
Civitas Investment Management Limited: Leading UK Social Impact Investment Manager Launches with AUM of £2 billion

From today all the investment management activities of the Civitas Group have been brought together under the new name of Civitas Investment Management Limited (“CIM” or “the Group”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200617005883/en/

CIM is a leading impact investor specialising in government-backed real assets that produce beneficial and sustainable social outcomes. Today, CIM announces expanded client mandates with combined assets under management (“AUM”) of £2 billion.

In all of CIM’s investment activities the Group aims to achieve measurable social impact at scale whilst delivering consistent long-term return profiles for investors together with value for money for the public purse. This is reflected in better personal outcomes and an enhanced quality of life for people living in the Group’s properties.

CIM’s performance in achieving these aims is monitored by independent social impact consultants who challenge and assist CIM in its investment frameworks.

Having established a leading presence in the UK for care-based housing and healthcare CIM is now expanding further into community based infrastructure and is planning to launch in the EU during the next 12 months.

New Website

To support these plans CIM has launched a new dedicated website that outlines its activities, social objectives and profiles the range of investment strategies that are delivered for institutional investors around the world (www.civitasim.com ).

Who We Are

CIM is a pioneer in introducing ethical, long-term private capital into the affordable housing and healthcare sectors, initially in England and Wales, then more widely in the UK and now with plans to access major EU countries.

In 2016 CIM launched Civitas Social Housing PLC, (“CSH”) as the first premium London listed real estate investment trust dedicated to investing in care-based housing for working age adults with long-term healthcare needs.

CSH is now a FTSE 250 company and the leading provider of care-based community housing in the UK with a portfolio of more than 600 buildings independently valued at nearly £900 million. Located across 164 local authority areas, supported by 117 specialist care providers, and 15 housing partners CSH provides bespoke, high quality adapted homes for over 4,200 people.

Reflecting the success of the strategy shareholders recently approved an extension of the CSH investment policy to enable the fund to work directly with the NHS, with other leading care providers and with major charities to provide accommodation and other social properties, in short supply within healthcare real estate.

CIM Investment Strategies

Having commenced investing in care-based social housing, CIM has now evolved a range of four broad and complementary investment strategies as follows:

  • Healthcare
  • Social and Affordable Housing
  • Social Infrastructure
  • Urban Regeneration

Across each of the four investment strategies are common themes and investment objectives that include:

  • 100% governmental income and support
  • Value for money for the public purse
  • Stable long-term cash generation
  • Low volatility and low correlation to economic cycles
  • Measurable social and ESG impact

Exclusive Partnerships

To assist in the delivery of the Group’s investment strategies CIM is pleased to have established exclusive partnerships with a number of leading investment houses and global real estate and infrastructure investors with whom CIM shares common ambitions and objectives.

Today CIM’s partners include:

  • Schroders, the global investment manager responsible for more than £500 billion of client assets across multiple investment strategies. CIM and Schroders are exclusive partners delivering new care-based housing, initially for approximately 2,000 people;
  • A leading Asia based global infrastructure and real estate investor has established an exclusive partnership with CIM to invest in housing based social infrastructure assets

Our Vision

The team of professionals working at CIM comes from a range of different backgrounds each offering expertise and operational experience in healthcare, social housing, real estate, social infrastructure and investment management.

They share a common conviction that responsible private capital can play a transformational role in the delivery of social assets that are themselves designed to enhance lives and communities. By investing for the long-term, with measurable social impact a fundamental requirement, the conditions are created for achieving sustainable and ethical returns for investors.

Andrew Dawber, Group Director at Civitas Investment Management Limited commented:

“We are delighted that CIM has reached an important investment milestone based on a growing number of client mandates. We are greatly encouraged by the opportunities in the near term future as we grow and build out our investment funds, deploying capital in projects in the UK, and in Europe in due course. We are experiencing strong and growing demand from portfolio managers who increasingly recognise the attractions of investing in the asset classes that CIM promotes.

We are especially proud of the team that we have built at CIM who each provide different perspectives towards the same goal, creating sustainable investment returns for the long term in projects that deliver genuine social good at a local level wherever that investment is made.”

-ENDS-

Notes to Editors:

Civitas Investment Management Limited (‘CIM’) is a leading impact investment manager that is dedicated to achieving long-term sustainable returns for the Group’s global investors by acquiring community-based assets that deliver positive social outcomes. CIM’s investments are supported by national governments and local municipalities that are themselves seeking to bring about positive societal change. CIM has an AUM of approximately £2 billion with a target to increase to £4 billion over the next two to three years following the build out of client mandates.

Among other impact investment ventures, CIM is the investment adviser to the London listed Civitas Social Housing PLC (“CSH”), the first dedicated London listed REIT to raise long-term sustainable, institutional capital to invest in care-based social homes and healthcare facilities across the UK. So far CIM has on behalf of CSH completed more than 120 individual transactions to build the largest portfolio of its kind in the UK that has been independently valued at approximately £900 million (www.civitassocialhousing.com ).

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye